Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vtv Therapeutics Inc's Business Segments
Vtv Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 37
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable99.9%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 37 | 99.9% |
Revenue by Product & Service Category - Q1 FY2026
- IP License45.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| IP License | $ 17 | 45.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vtv Therapeutics Inc
Vtv Therapeutics Inc. is a biopharmaceutical company that is focused on the discovery and development of innovative treatments for various diseases. The company was founded in 2002 and is headquartered in High Point, North Carolina, United States. It operates as a subsidiary of Vtv Therapeutics Holdings LLC.
The core expertise of Vtv Therapeutics lies in the field of drug discovery and the development of small molecule drugs. The company utilizes its proprietary drug discovery platform, TTP Translational Technology, to identify and validate drug targets and develop potential therapeutics for a range of unmet medical needs.
One of the key areas of focus for Vtv Therapeutics is the development of treatments for metabolic disorders, including type 2 diabetes. The company has developed several drug candidates targeting the glucagon receptor, which is implicated in the regulation of blood sugar levels. These candidates aim to improve glycemic control in patients with diabetes by modulating glucagon receptor activity.
Vtv Therapeutics is also involved in developing treatments for various other diseases, including motor neuron diseases, Alzheimer's disease, and inflammatory disorders. The company's drug candidates target specific molecular pathways involved in these diseases and aim to address underlying disease mechanisms.
In addition to its internal drug development programs, Vtv Therapeutics also actively engages in strategic collaborations with pharmaceutical companies, academic institutions, and other research organizations. These collaborations allow the company to leverage external expertise and resources to accelerate the development of its drug candidates.
Vtv Therapeutics places a strong emphasis on conducting rigorous preclinical and clinical studies to evaluate the safety and efficacy of its drug candidates. The company follows a systematic approach towards drug development, adhering to regulatory guidelines and standards.
Overall, Vtv Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of various diseases. With its proprietary drug discovery platform and strategic collaborations, the company aims to bring innovative and effective therapies to patients in need.
The core expertise of Vtv Therapeutics lies in the field of drug discovery and the development of small molecule drugs. The company utilizes its proprietary drug discovery platform, TTP Translational Technology, to identify and validate drug targets and develop potential therapeutics for a range of unmet medical needs.
One of the key areas of focus for Vtv Therapeutics is the development of treatments for metabolic disorders, including type 2 diabetes. The company has developed several drug candidates targeting the glucagon receptor, which is implicated in the regulation of blood sugar levels. These candidates aim to improve glycemic control in patients with diabetes by modulating glucagon receptor activity.
Vtv Therapeutics is also involved in developing treatments for various other diseases, including motor neuron diseases, Alzheimer's disease, and inflammatory disorders. The company's drug candidates target specific molecular pathways involved in these diseases and aim to address underlying disease mechanisms.
In addition to its internal drug development programs, Vtv Therapeutics also actively engages in strategic collaborations with pharmaceutical companies, academic institutions, and other research organizations. These collaborations allow the company to leverage external expertise and resources to accelerate the development of its drug candidates.
Vtv Therapeutics places a strong emphasis on conducting rigorous preclinical and clinical studies to evaluate the safety and efficacy of its drug candidates. The company follows a systematic approach towards drug development, adhering to regulatory guidelines and standards.
Overall, Vtv Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of various diseases. With its proprietary drug discovery platform and strategic collaborations, the company aims to bring innovative and effective therapies to patients in need.
Vtv Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. The company operates primarily within the sectors of drug development, with a specific focus on treatments related to metabolic diseases, neurodegenerative disorders, and other illnesses requiring specialized therapeutic interventions.
Segments
1. Metabolic Diseases:
- This segment centers on the development of treatments aimed at metabolic disorders, including diabetes and obesity. Vtv is engaged in research to discover and develop new pharmacological interventions that can address the underlying mechanisms of these diseases, targeting key metabolic pathways that influence insulin sensitivity, weight management, and overall metabolic health.
2. Neurodegenerative Disorders:
- Vtv Therapeutics develops therapies aimed at neurodegenerative conditions, including Alzheimer’s disease and other cognitive impairments. The focus is on creating drugs that can stabilize or improve cognitive function by targeting specific biochemical pathways associated with neurodegeneration.
3. Other Therapeutic Areas:
- In addition to metabolic diseases and neurodegenerative disorders, Vtv explores therapeutics in various other health conditions. This includes a diverse portfolio that may involve treatments for autoimmune diseases, cancer, and cardiovascular conditions, reflecting their commitment to addressing a broad spectrum of unmet medical needs.
Products
1. Oral Therapeutics:
- Vtv Therapeutics specializes in developing oral therapies that can be more accessible and easier for patients to adhere to. These formulations are designed to ensure improved absorption and bioavailability in the body, enhancing effectiveness and patient compliance.
2. Injectable Therapies:
- In conjunction with their oral products, Vtv is also involved in the development of injectable therapies that provide alternative therapeutic options for patients who may not respond adequately to oral medications. These products often target diseases that require rapid therapeutic effects or sustained release of the active compound over time.
3. Combination Therapies:
- Recognizing the complexity of treating multifactorial diseases, Vtv Therapeutics also looks at combination therapies that harness the synergetic effects of different active ingredients to achieve better clinical outcomes. This approach is particularly relevant in conditions like diabetes and obesity.
Services
1. Clinical Trials:
- Vtv plays a significant role in the design and execution of clinical trials to evaluate the efficacy and safety of their pipeline products. They conduct both phase I and phase II trials and may also engage in later stage trials in partnership with other research organizations or pharmaceutical companies.
2. Research and Development:
- The company invests heavily in research and development to push the boundaries of existing therapies. This includes both preclinical research to discover novel drug candidates and ongoing studies to optimize existing products for improved therapeutic outcomes.
3. Regulatory Compliance:
- Vtv Therapeutics ensures that all its products meet stringent regulatory requirements. They work closely with agencies like the FDA to navigate the complex approval processes for their therapeutic offerings, ensuring that safety and efficacy standards are met.
4. Strategic Partnerships and Collaborations:
- The company actively seeks partnerships with academic institutions, research organizations, and other biotechnology companies to leverage external expertise and resources. These collaborations can expedite the development process and enhance their ability to bring innovative therapies to market.
Conclusion
Vtv Therapeutics Inc. has created a diverse range of segments, products, and services focusing on critical areas of unmet medical need. Through its commitment to research and development, the company seeks to establish itself as a leader in innovative therapeutic solutions for metabolic and neurodegenerative diseases while also exploring wider applications in other health domains. The emphasis on oral and injectable therapies, along with strategic collaborations, positions Vtv Therapeutics as a prominent player in the biopharmaceutical landscape.
Segments
1. Metabolic Diseases:
- This segment centers on the development of treatments aimed at metabolic disorders, including diabetes and obesity. Vtv is engaged in research to discover and develop new pharmacological interventions that can address the underlying mechanisms of these diseases, targeting key metabolic pathways that influence insulin sensitivity, weight management, and overall metabolic health.
2. Neurodegenerative Disorders:
- Vtv Therapeutics develops therapies aimed at neurodegenerative conditions, including Alzheimer’s disease and other cognitive impairments. The focus is on creating drugs that can stabilize or improve cognitive function by targeting specific biochemical pathways associated with neurodegeneration.
3. Other Therapeutic Areas:
- In addition to metabolic diseases and neurodegenerative disorders, Vtv explores therapeutics in various other health conditions. This includes a diverse portfolio that may involve treatments for autoimmune diseases, cancer, and cardiovascular conditions, reflecting their commitment to addressing a broad spectrum of unmet medical needs.
Products
1. Oral Therapeutics:
- Vtv Therapeutics specializes in developing oral therapies that can be more accessible and easier for patients to adhere to. These formulations are designed to ensure improved absorption and bioavailability in the body, enhancing effectiveness and patient compliance.
2. Injectable Therapies:
- In conjunction with their oral products, Vtv is also involved in the development of injectable therapies that provide alternative therapeutic options for patients who may not respond adequately to oral medications. These products often target diseases that require rapid therapeutic effects or sustained release of the active compound over time.
3. Combination Therapies:
- Recognizing the complexity of treating multifactorial diseases, Vtv Therapeutics also looks at combination therapies that harness the synergetic effects of different active ingredients to achieve better clinical outcomes. This approach is particularly relevant in conditions like diabetes and obesity.
Services
1. Clinical Trials:
- Vtv plays a significant role in the design and execution of clinical trials to evaluate the efficacy and safety of their pipeline products. They conduct both phase I and phase II trials and may also engage in later stage trials in partnership with other research organizations or pharmaceutical companies.
2. Research and Development:
- The company invests heavily in research and development to push the boundaries of existing therapies. This includes both preclinical research to discover novel drug candidates and ongoing studies to optimize existing products for improved therapeutic outcomes.
3. Regulatory Compliance:
- Vtv Therapeutics ensures that all its products meet stringent regulatory requirements. They work closely with agencies like the FDA to navigate the complex approval processes for their therapeutic offerings, ensuring that safety and efficacy standards are met.
4. Strategic Partnerships and Collaborations:
- The company actively seeks partnerships with academic institutions, research organizations, and other biotechnology companies to leverage external expertise and resources. These collaborations can expedite the development process and enhance their ability to bring innovative therapies to market.
Conclusion
Vtv Therapeutics Inc. has created a diverse range of segments, products, and services focusing on critical areas of unmet medical need. Through its commitment to research and development, the company seeks to establish itself as a leader in innovative therapeutic solutions for metabolic and neurodegenerative diseases while also exploring wider applications in other health domains. The emphasis on oral and injectable therapies, along with strategic collaborations, positions Vtv Therapeutics as a prominent player in the biopharmaceutical landscape.